ROME Italy - CSL Behring

Foto MCristof for SMC media
22•ROME• Italy
24 February
2012
www.
eahad2012
.org
5th EAHAD
Annual Congress
European Association for Haemophilia and Allied Disorders
Venue
Ergife Palace Hotel and Congress Centre
Via Aurelia, 619
00165 Rome, Italy
Language
English is the official language of the Congress.
No simultaneous translation will be available.
Continuing medical education
The 5th EAHAD Congress has been recognized by EHA-CME
Unit as CME event for Hematologists and will grant 9.5
credits to attending participants.
Accreditation for Italian Continuing Medical Education
has also been obtained for the following specialties:
haematology, medical genetics, internal medicine, pediatrics,
orthopaedics, transfusion medicine, clinical pathology,
biology, psycology, nursing sciences.
The number of Italian CME credits granted to participants
attending the whole Congress is 7.5.
Liability
The Congress Organizers cannot accept liability for personal injuries
sustained or for loss or damage to property belonging to Congress
Partecipants, either during or as a result of the Congress. Please check the
validity of your insurance.
5th EAHAD
www.eahad2012.org
22•24 February, 2012 Rome - Italy
The Association
The European Association for Haemophilia and Allied
Disorders is a multi-disciplinary association of healthcare
professionals who provide care for individuals with
haemophilia and other bleeding disorders.
EAHAD purpose is to promote clinical care, education and
research for this group of patients across the continent.
Visit the Association website at www.eahad.org.
EAHAD Executive Committee
Pier Mannuccio Mannucci, President
Jan Astermark, Vice-President
Philippe de Moerloose, Secretary
Christopher A. Ludlam, Treasurer
Gerry Dolan, Company Secretary
Kathelijn Fischer
Christine Harrington
Cedric Hermans
Johannes Oldenburg
Elena Santagostino
Jerzy Windyga
European Association for Haemophilia and Allied Disorders Ltd Limited
Company registered in England No. 06373427
Registered as a Charity in England No. 1125081
1
Wednesday, February 22nd
12.00-19.00
Registration
14.30-16.00
Satellite Symposium - Factor VIII inhibitor: the
18.00-19.30Satellite Symposium - Haemophilia with
inhibitors: current state and future options
Novo Nordisk
Chairs: M.G. Mazzucconi (Italy), P.M. Mannucci (Italy)
Introduction
most cogent unresolved issue in haemophilia
A. Obergfell (Switzerland)
Grifols, Kedrion, LFB
Early treatment means rapid bleeding control
Chairs: F. Peyvandi (Italy), J. Goudemand (France)
M. Morfini (Italy)
Risk factors for inhibitors: can they be
controlled?
• In previously untreated patients
The importance of treatment optimization in
children
E. Santagostino (Italy)
E. Santagostino (Italy)
• In previously treated patients
Current management of ITI
C. Hay (UK)
M.E. Mancuso (Italy)
Immune tolerance induction: the optimal
choice of factor VIII product
Future of haemostasis in inhibitor patients:
beyond current treatment
C. Escuriola Ettingshausen (Germany)
16.00-16.30
S.E. Bjørn (Novo Nordisk, Denmark)
Break
16.30-18.00Satellite Symposium - Managing haemophilia
for life - Thoughts on safety and efficacy
Discussion and conclusions
19:30
EAHAD Executive Committee Meeting
Pfizer
Chairs: P.M. Mannucci (Italy), M. Makris (UK)
Welcome and introduction
Co-Chairmen
Inhibitor development: how to assess the risk
J. Astermark (Sweden)
Monitoring safety and efficacy over the longterm: the role of registries
K. Fischer (the Netherlands)
The science of switching
Thursday, February 23rd
8.00-9:30Satellite Symposium - A natural pathway to
longer lasting haemophilia therapies
Swedish Orphan Biovitrum and Biogen Idec
Hemophilia
C. Hay (UK)
Chairman and Co-chair: J. Astermark (Sweden),
Optimal prophylaxis in haemophilia B: new
developments
S. James (Sweden)
L. Valentino (USA)
A new age in haemophilia management
Q&A
Facilitated by Co-Chairmen
• Chairmen introduction
Summary
Co-Chairmen
• Extending treatment through life and
disease
M. Makris (UK)
2
Fc fusion technology: a new approach for drug
development in haemophilia
• Fc fusion technology
• European Haemophilia Therapy
Standardization Board (EHTSB) and the Agerelated DeVelopments And Comorbidities in
haemophilia (ADVANCE) group
P. Lind (Sweden)
G. Dolan (UK)
• Assays – A technical overview
• European initiative to prevent joint damage
in haemophilia children with inhibitors
(ENJOIH) - a prospective study
J.M. Sommer (USA)
Longer lasting coagulation factors
• Clinical investigation of rFVIIIFc – a longer
lasting coagulation factor VIII
R. Klamroth (Germany)
E. Santagostino (Italy)
12.00-12.30
Break
12.30-14.00
Lunch Satellite Symposium - Prophylaxis for life?
• Individualized treatment - Coagulation factor
Bayer
pharmacokinetics and implications for treatment
J. Pasi (UK)
Chairman and Co-chair: J. Astermark (Sweden),
M. Morfini (Italy)
Questions and panel discussion
09.30-10.30Scientific
Welcome
J. Astermark (Sweden)
Session 1
Interactive case discussions:
• Personalized prophylaxis: a “good
companion” for life
Chairs: P.M. Mannucci (Italy), J. Astermark (Sweden)
The European Haemophilia Safety Surveillance
System (EUHASS)
C. Santoro (Italy)
M. Makris (UK)
• Obstacles to treatment: overcoming
inhibitors in prophylaxis
EAHAD working parties:
P.A. Holme (Norway)
• IPD meta-analysis to investigate risk factors
for inhibitor development
Current clinical evidence
R. Klamroth (Germany)
A. Iorio (Italy)
Pharmacokinetics – are there differences
between children and adults?
• EAHAD working party on mutation
databases
S. Björkman (Sweden)
C. Ludlam (UK)
Discussion and conclusion
J. Astermark (Sweden), M. Morfini (Italy)
• EAHAD working party on factor VIII assay
discrepancies
J. Oldenburg (Germany)
• EAHAD working party on epidemiology and
management of rare bleeding disorders
F. Peyvandi (Italy)
10.30-11.00
14.00-14.30
14.30-16.00Scientific
Session 2
Chairs: C.A. Ludlam (UK), J. Windyga (Poland)
Break
New drugs for hepatitis C: their role in
haemophilia and allied disorders
11.00-12.00 Other studies:
C. Colombo (Italy)
• The SIPPET study: rationale and current state
Outcome assessement in haemophilia therapy
P.M. Mannucci (Italy)
V. Blanchette (Canada)
• Factor VIII prophylaxis and inhibitor
development in previously untreated
patients with severe haemophilia A: the
RODIN study
M. van den Berg (the Netherlands)
Break
Ultrasound diagnosis of haemophilic
arthropathy
C. Martinoli (Italy)
16.00-16.30
Break
3
16.30-17.30Scientific
Session 3
12.45-14.15
Chairs: C. Hermans (Belgium), M. Makris (UK)
Coordinators: J. Astermark (Sweden),
Prophylaxis in rare bleeding disorders
E. Santagostino (Italy), J. Windyga (Poland)
P. de Moerloose (Switzerland)
Factor XIII deficiency: diagnostic and
therapeutic issues
H.P. Kohler (Switzerland)
Lunch Session Poster Viewing And Manning
14.15-14.30
Break
14.30-16.00Scientific
Session 6
17.30-18.30
EAHAD General Assembly
Chairs: J. Oldenburg (Germany),
20.00-22.00
Congress Dinner
VWF, angiodysplasia and endothelial
progenitor cells: novel insights from basic
science
P. de Moerloose (Switzerland)
A.M. Randi (UK)
The value of genotyping in predicting poor
response to desmopressin in mild haemophilia
and von Willebrand disease
Friday, February 24th
8.30-10.30Scientific
Session 4
G. Castaman (Italy)
Gene theraphy trial in severe haemophilia B
E. Tuddenham (UK)
Chairs: K. Fischer (the Netherlands), G. Dolan (UK)
Tranexamic acid: the haemostatic drug of
choice
M. Levi (the Netherlands)
Global coagulation tests: their role in
haemophilia and acquired coagulation
disorders
Y. Dargaud (France)
The ITI Study: clinical implications
C. Hay (UK)
The use of the clinical trial design in
haemophilia: methodological considerations
A. Iorio (Italy)
10.30-11.00
Break
11.00-12.30Scientific
Session 5
Chairs: W. Schramm (Germany), F. Peyvandi (Italy)
EMA and FDA requirements for licensing new
haemophilia products: do they truly provide
answers on safety/efficacy?
L. Aledort (USA), E. Santagostino (Italy),
C. Male (Austria)
12.30-12.45
Break
Conclusions and CME questionnaire
(for Italian delegates only)
With the contribution of:
Haemophilia
Provider:
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Ufficio Formazione _ Via Francesco Sforza, 28 - 20122 Milan • Italy
Organizing secretariat:
SMC Media S.r.l
www.smc-media.com
Via Giovenale, 7 - 20136 Milan • Italy
T: +39 02 3656 2222 • +39 02 5810 2846 • +39 02 8716 7183
F: +39 02 9366 3665 • C: +39 335 6530 304
E-mail: [email protected] • [email protected]